Peretinoin, an Acyclic Retinoid, for the Secondary Prevention of Hepatocellular Carcinoma

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Jan 13

PMID 33435572

Citations 3

Authors

Hyun Young Woo

So Young Yoo

Jeong Heo

Affiliations

Soon will be listed here.

Abstract

The high rates of hepatocellular carcinoma (HCC) recurrence after initially successful curative therapy emphasize ongoing unmet needs to prevent or reduce HCC recurrence. Retinoid acid (RA), a metabolite of vitamin A and its related analogues (termed retinoids) has been suggested as a promising chemotherapeutic agent in cancer treatment. The synthetic oral retinoid peretinoin is the only agent for the secondary chemoprevention of HCC after curative therapy that is currently well applied into clinical development. Here we present an updated summary of the molecular pathogenesis of HCC and of preclinical and clinical findings with peretinoin, including its clinical characteristics, safety and tolerability profile and future perspectives for clinical use.

Citing Articles

Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma.

Kokudo N, Kokudo T, Song P, Tang W Glob Health Med. 2024; 6(3):170-173.

PMID: 38947413 PMC: 11197156. DOI: 10.35772/ghm.2024.01002.

Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma.

Kumar S, Pandey A Curr Oncol. 2023; 30(2):1363-1380.

PMID: 36826066 PMC: 9955633. DOI: 10.3390/curroncol30020105.

Retinoids in the Pathogenesis and Treatment of Liver Diseases.

Melis M, Tang X, Trasino S, Gudas L Nutrients. 2022; 14(7).

PMID: 35406069 PMC: 9002467. DOI: 10.3390/nu14071456.

References

Uray I, Shen Q, Seo H, Kim H, Lamph W, Bissonnette R . Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. J Biol Chem. 2008; 284(1):345-353. PMC: 2610495. DOI: 10.1074/jbc.M804721200. View

Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y . Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007; 22(11):1929-35. DOI: 10.1111/j.1440-1746.2006.04707.x. View

Huang J, Bi Y, Zhu G, He Y, Su Y, He B . Retinoic acid signalling induces the differentiation of mouse fetal liver-derived hepatic progenitor cells. Liver Int. 2009; 29(10):1569-81. DOI: 10.1111/j.1478-3231.2009.02111.x. View

Tan C . Peretinoin as an adjuvant therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2016; 10(11):1201-1210. DOI: 10.1080/17474124.2016.1238303. View

Ma Y, Koza-Taylor P, DiMattia D, Hames L, Fu H, Dragnev K . Microarray analysis uncovers retinoid targets in human bronchial epithelial cells. Oncogene. 2003; 22(31):4924-32. DOI: 10.1038/sj.onc.1206728. View

Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. PMC: 6813818. DOI: 10.1038/s41575-019-0186-y. View

Zender L, Villanueva A, Tovar V, Sia D, Chiang D, Llovet J . Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 2010; 52(6):921-9. PMC: 2905725. DOI: 10.1016/j.jhep.2009.12.034. View

Hu W, Feng Z, Eveleigh J, Iyer G, Pan J, Amin S . The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis. 2002; 23(11):1781-9. DOI: 10.1093/carcin/23.11.1781. View

Roskams T, Yang S, Koteish A, Durnez A, Devos R, Huang X . Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol. 2003; 163(4):1301-11. PMC: 1868311. DOI: 10.1016/S0002-9440(10)63489-X. View

10.

Shimizu M, Shirakami Y, Imai K, Takai K, Moriwaki H . Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis. J Carcinog. 2012; 11:11. PMC: 3515920. DOI: 10.4103/1477-3163.100398. View

11.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

12.

Okada H, Honda M, Campbell J, Sakai Y, Yamashita T, Takebuchi Y . Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res. 2012; 72(17):4459-71. DOI: 10.1158/0008-5472.CAN-12-0028. View

13.

Funaki M, Kitabayashi J, Shimakami T, Nagata N, Sakai Y, Takegoshi K . Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo. Sci Rep. 2017; 7(1):16978. PMC: 5717167. DOI: 10.1038/s41598-017-17285-2. View

14.

Okusaka T, Ueno H, Ikeda M, Morizane C . Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. Hepatol Res. 2011; 41(6):542-52. DOI: 10.1111/j.1872-034X.2011.00800.x. View

15.

Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K . Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 2006; 44(4):891-5. DOI: 10.1002/hep.21341. View

16.

Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S . Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38(2):200-7. DOI: 10.1016/s0168-8278(02)00360-4. View

17.

Gao Q, Wang X, Qiu S, Yamato I, Sho M, Nakajima Y . Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009; 15(3):971-9. DOI: 10.1158/1078-0432.CCR-08-1608. View

18.

Xu L, Liu C . Role of liver stem cells in hepatocarcinogenesis. World J Stem Cells. 2014; 6(5):579-90. PMC: 4178257. DOI: 10.4252/wjsc.v6.i5.579. View

19.

Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H . Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology. 1993; 188(1):79-83. DOI: 10.1148/radiology.188.1.8390073. View

20.

Nishimura N, Kaji K, Kitade M, Aihara Y, Sato S, Seki K . Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats. BMC Cancer. 2018; 18(1):1164. PMC: 6260898. DOI: 10.1186/s12885-018-5099-6. View